Second biosimilar from Amgen and Allergan approved by FDA

By Maggie Lynch

- Last updated on GMT

(Image: Getty/psisa)
(Image: Getty/psisa)

Related tags Amgen Allergan Herceptin Biosimilars Biologics Fda FDA approval Breast cancer

Amgen’s biosimilars portfolio reaches a milestone after its Herceptin biosimilar, Kanjinti, developed in collaboration with Allergan, was approved by the US FDA.

The US Food and Drug Administration (FDA) approved Kanjinti (trastuzumab-anns) from Amgen and Allergan for all approved indications of the reference drug, Roche’s Herceptin (trastuzumab), including the treatment of HER2-overexpressing adjuvant and metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Kanjinti was approved after demonstrating no clinically meaningful differences to the reference product.

Currently, Kanjinti is the only biosimilar that incorporates the evaluation of a single transition in the clinical study to demonstrate similar safety and immunogenicity in patients who previously received Herceptin.

With this approval, two of the four biosimilars developed per a 2011 collaboration between Amgen and Allergan have received FDA approval. Kanjinti is the 10th approved biosimilar in Amgen’s portfolio, with three drugs approved in the US and three approved in the EU, including Mvasi​ (bevacizumab-awwb) a biosimilar for Roche’s Avastin (bevacizumab).

The collaboration between the two companies sees Amgen responsible for development, manufacturing, and the initial commercialization of the oncology antibody drug candidates, while Allergan provides funding.

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more